Boston Scientific closes acquisition of Vertiflex

395

Boston Scientific has announced the close of its acquisition of Vertiflex, a privately-held company that developed and commercialised the Superion Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS).

The acquisition of Vertiflex adds the only FDA-approved, commercially-available, minimally-invasive interspinous spacer to the industry-leading pain management portfolio from Boston Scientific, which also includes spinal cord stimulation and radiofrequency ablation.

“The addition of the Vertiflex procedure to our pain management portfolio advances our pain category leadership strategy, while also providing physicians with additional non-opioid pain management solutions that can help improve the lives of the growing number of patients suffering from chronic pain,” said Maulik Nanavaty, president, Neuromodulation, Boston Scientific.

As noted in the definitive agreement announcement, the transaction consists of US$465 million in upfront cash and additional payments contingent on commercial milestones for the next three years.

(Visited 123 times, 1 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here